Patent litigation attorney

Matthew S. Freimuth

3 tracked appearances — 1 plaintiff · 2 defendant.

Specialty & background

Let me verify the case details and his PTAB experience.

Matthew S. Freimuth — Willkie Farr & Gallagher LLP (New York)

Focus areas. Freimuth is a partner in Willkie's Litigation and Intellectual Property Departments and describes his practice as complex civil and IP litigation, with a specialty in patent and technology disputes and particular expertise at the intersection of antitrust and IP (Willkie firm bio; Legal 500). The tracked patent matters and his published experience skew toward life sciences and biotechnology — the Pfizer/BioNTech COVID-19 vaccine (lipid nanoparticle) litigation, Pfizer/Hospira epinephrine injectables, Regeneron's aflibercept/biosimilar actions against Celltrion and Mylan, and LaJolla Pharmaceutical's patent assertion over a septic-shock drug — with additional work in medical devices (Insulet's Omnipod insulin pump) and mechanical/industrial equipment patent appeals against Weber, Inc. Third-party docket-aggregator data also classifies his case mix as heavy in biotechnology and semiconductor/optics, with smaller shares in communications, chemical, and mechanical/manufacturing arts. Earlier CLE work by him addressed Hatch-Waxman settlements, patent assertion entities, and standard-essential patents, consistent with that antitrust/IP crossover profile.

Side preference. The tracked appearances are 2 defendant-side to 1 plaintiff-side, and the wider record is consistent with a defense-leaning practice on behalf of large operating companies: Netflix in the VideoLabs campaign, Pfizer and Pharmacia & Upjohn in Delaware, Hospira in ANDA litigation and appeals, and Insulet as defendant. The plaintiff-side work is primarily as patent owner's counsel (LaJolla asserting its own patents; Regeneron as patentee). He does not appear to be an NPE/PAE-side prosecutor; he has publicly presented on PAEs from the defendant/antitrust-compliance perspective.

Notable matters. In the Netflix/VideoLabs disputes he was on Netflix's Federal Circuit team (with Aliza George Carrano, Dane Sowers, and Devon Edwards) in appeals from PTAB final written decisions. The '790 patent IPR ended with all challenged claims held unpatentable, and the Federal Circuit affirmed on May 12, 2026 in VideoLabs, Inc. v. Netflix, Inc., No. 25-1131 (Rule 36, nonprecedential). A companion appeal involving the '559 patent, VL Collective IP, LLC v. Netflix, Inc., No. 25-1132, was affirmed on the merits on August 10, 2026, with the court rejecting VideoLabs' claim-construction arguments. He was also on the Willkie team (led by Sara Tonnies Horton) that obtained dismissal of Alnylam's patent infringement claims against Pfizer in the District of Delaware concerning the Comirnaty COVID-19 vaccine, recognized with an AmLaw Litigation Daily "Litigator of the Week" shout-out in August 2025; he was admitted pro hac vice for Pfizer in that case in March 2025. His Willkie bio also credits him on a district court win and successful Federal Circuit appeal for Pfizer/Hospira in epinephrine injectable litigation, and on the Regeneron/aflibercept matters. (Note: a non-patent win — the Tenth Circuit ruling for Edwell Inc. in a Lanham Act case — is also attributed to him.)

PTAB/IPR and credentials. He appears regularly in Federal Circuit appeals arising from IPR proceedings, and the Netflix IPRs at issue list him as appellate counsel; the PTAB trial teams in those matters were led by USPTO-registered practitioners from his firm, and I found no evidence that Freimuth himself is a registered patent attorney. The tracked role labels ("appellate associate," "counsel") appear to be docket-level designations and conflict with the firm's identification of him as a partner with more than 20 years of practice; treat those labels with caution. Bar and education per the firm bio: admitted in New York and Connecticut (plus SDNY, EDNY, NDNY, D. Conn., and the Second Circuit); Georgetown University Law Center, J.D. 2001; Worcester Polytechnic Institute, B.S. 1998. He also writes and speaks on antitrust and IP topics, including commentary on the Federal Circuit's EcoFactor v. Google en banc damages decision and the Supreme Court's Amgen v. Sanofi enablement ruling.

Firms

Roles

  • appellate associate1
  • appellate counsel1
  • counsel1

Cases (3)